CN1110557A - Silver nitrate ointment - Google Patents
Silver nitrate ointment Download PDFInfo
- Publication number
- CN1110557A CN1110557A CN 94119842 CN94119842A CN1110557A CN 1110557 A CN1110557 A CN 1110557A CN 94119842 CN94119842 CN 94119842 CN 94119842 A CN94119842 A CN 94119842A CN 1110557 A CN1110557 A CN 1110557A
- Authority
- CN
- China
- Prior art keywords
- ointment
- silver nitrate
- water
- glycerol
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229910001961 silver nitrate Inorganic materials 0.000 title claims abstract description 44
- 239000002674 ointment Substances 0.000 title claims abstract description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 19
- 235000019322 gelatine Nutrition 0.000 claims abstract description 19
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004323 potassium nitrate Substances 0.000 claims abstract description 7
- 235000010333 potassium nitrate Nutrition 0.000 claims abstract description 7
- 235000011187 glycerol Nutrition 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 10
- 229940008099 dimethicone Drugs 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 5
- 244000248349 Citrus limon Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000001828 Gelatine Substances 0.000 claims description 3
- 239000004568 cement Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004332 silver Substances 0.000 abstract description 6
- 229910052709 silver Inorganic materials 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- -1 silver ions Chemical class 0.000 abstract description 4
- 239000002574 poison Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 abstract 1
- 206010051548 Burn infection Diseases 0.000 abstract 1
- 240000004307 Citrus medica Species 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010048038 Wound infection Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 1
- 230000000249 desinfective effect Effects 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229920002545 silicone oil Polymers 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 17
- 229960003600 silver sulfadiazine Drugs 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000002847 Surgical Wound Diseases 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 206010051814 Eschar Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 229940006461 iodide ion Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000009602 toxicology test Methods 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940048368 flamazine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- NKLZSBHAQMKTDZ-UHFFFAOYSA-N pyrimidine silver Chemical compound [Ag].N1=CN=CC=C1 NKLZSBHAQMKTDZ-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The silver nitrate ointment belonging to hydrophilic one containing silver ions is prepared from silver nitrate (0.1-0.2%) as main component, glycerin (15%), dimethyl silicone oil (3%), gelatin (2%), carboxymethyl vitamine sodium (3.8%), beta-cyclodextrin (2%), citron yellow (0.005%), potassium nitrate (0.005%) and water, and may be used to treat burn and wound infection with advantages of high curative effect, no hypersensitivity reaction, strong disinfecting power and low poison.
Description
The present invention relates to surgical medicine, particularly argentiferous ionic hydrophilic ointment and compound method thereof.
Handle surgical wound with silver and its esters, all on the books at all times.Silver nitrate is a kind of of silver salt, and the silver nitrate of high concentration for example silver stick has corrosiveness, and the wound surface of human in the granulation hyperplasia of small size early arranged; The silver nitrate of low concentration for example 0.5% aqueous solution has antibiotic astriction, once voguish with its treatment large-area burns, a large amount of experiment and clinical practices prove, use 0.5% silver nitrate solution soak, really can prevent and treat burn wound's septicemia, reach and improve the purpose that cure rate reduces mortality rate and disability rate.The problem that exists is: 1, meet light and become black, hinder wound surface to observe; 2, infiltration is forced down, and upsets fluid and electrolyte balance; 3, free silver ions rapidly and the protein binding of transudate, bactericidal action is difficult to lastingly; 4, be difficult for being penetrated into deep tissue; 5, the silver nitrate metabolism causes positive hemoglobin disease once in a while.Just because of this, silver nitrate aqueous solution is just replaced by silver sulfadiazine ointment.United States Patent (USP) 3761590(1975) be exactly this class medicine for external use Chinese patent CN 88101699A(1988).It has overcome the problems that silver nitrate aqueous solution exists, so since nineteen sixty-eight, this ointment occupies critical role in external use burn treating medicine always.But silver sulfadiazine also has some shortcomings, and for example: 1, the anaphylaxis of part or whole body happens occasionally; 2, Resistant strain increases day by day; 3, there is zest the part, and patient can feel scorching hot and sharp during external application; 4, can produce inhibitory action to epidermal growth during valid density; 5, after sulfadiazine absorbs from wound surface, renal function there is certain negatively influencing.So over nearly 10 years, the expert is striving to find the succedaneum of silver sulfadiazine both at home and abroad always.
The objective of the invention is to develop a kind of advantage that can keep and develop silver-colored aqueous solution of orthonitric acid and silver sulfadiazine ointment by the change of dosage form and the improvement of substrate, overcome their shortcomings separately, develop the new drug that a kind of good effect, low, easy to use, the low-cost control burn of toxicity and other surgical wound infect.
Purpose of the present invention adopts following technical scheme to realize:
Through experiment repeatedly, the content of determining principal agent silver nitrate in the silver nitrate ointment is 0.1～0.2%, selects for use 5 kinds of water-soluble basees commonly used to add the ointment that an amount of dimethicone is made simultaneously, filters out following proper formulation and has determined production technology by germ experiment.
(1) silver nitrate ointment prescription (weight %)
A. principal agent:
Silver nitrate 0.1～0.2
B. accessory drugs:
Beta-schardinger dextrin-2.0
Sodium carboxymethyl cellulose 3.8
Gelatin 2.0
Dimethicone 3.0
Potassium nitrate 0.005
Glycerol 15.00
Lemon yellow 0.005
C. water surplus
A+B+C=100 weight %
(2) technology:
1, gets gelatin and add 40 milliliters in warm water, soak 80 ℃ of expansion post-heating, make it dissolve into rubber cement;
2, get glycerol and add in the gelatine size, stir glycerol gelatin matrix;
3, get the sodium carboxymethyl cellulose dimethicone, add in the glycerol gelatin matrix, stir;
4, get beta-schardinger dextrin-and add 20 milliliters in water, heat 60 ℃ of dissolvings;
5, get silver nitrate, potassium nitrate adds 5 milliliters in water, dissolving back adds in the beta-schardinger dextrin-liquid, adds in the glycerol gelatin matrix to stir again;
6, getting the dissolving of lemon yellow adding excess water stirs back the adding in the above-mentioned substrate;
7, uniform ointment is put taken out the bubble that degass in the vacuum chamber;
8, Packaging Bottle is cleaned the cold drying sterilization;
9, with ointment sampling chemical examination, quantitative filling, warehouse-in seals, labels, cases.
Silver nitrate ointment of the present invention has been carried out pharmacodynamics and toxicology test:
(1) Pharmacodynamic test of active extract:
1, extracorporeal bacteria inhibitor test: silver nitrate ointment all has stronger inhibitory action to the common bacterial infection of fire victim, is 16 mcg/ml to the minimum inhibitory concentration (MIC) of bacillus pyocyaneus, is 31 mcg/ml to golden staphylococci.
2, bacteriostatic test in the body: to rabbit and the test of burned rats treatment of infection, the result of the subeschar bacterial count of blank group or matched group and administration group has notable difference, proves that this ointment fungistatic effect is remarkable.
(2) toxicology test:
1, acute toxicity test: the acute toxicity test of intact skin and the acute toxicity test of corrupted skin prove that all silver nitrate ointment does not have the acute toxicity effect.
2, long term toxicity test: successive administration 45 days, 5 times of high dose group behaviour consumption are not seen any toxic reaction, think this product safety non-toxic.
3, skin irritation test: no matter 4 rabbit are to observe at that time after the administration, still visit to a week in 24 hours, and the part of its dispenser there is no erythema, phenomenons such as edema.
4, skin anaphylactic test: the number of animals of skin rubefaction or edema occurs according to every treated animal, divided by the animal subject sum, calculate the sensitization rate, each administration group and blank matrix group sensitization rate are zero.
5, the influence of human epidermal cell growth is observed:
With blank group contrast proof 0.1% silver nitrate ointment epidermal growth there is not inhibitory action with 0.1%, 0.5% silver nitrate ointment and 2% sulfadiazine group ointment.
Three, relevant silver nitrate ointment quality research:
(1) physicochemical constant:
Silver nitrate ointment is yellow or yellowish-brown water-soluble ointment, evenly, fine and smooth, be easy to coating, be easy to clean, pH value 6.5～6.8 is faintly acid, and suitable HLB value and water number are arranged.
(2) silver nitrate assay:
Adopt iodide ion to select determination of electrode residue iodide ion concentration, thus indirect determination concentration of silver ions method.
(3) silver nitrate ointment stability experiment:
Silver nitrate ointment is tested after the packing in the polypropylene plastics bottle that adopts lucifuge and favorable sealing property, shows 20 ± 5 ℃ of stability test results, deposits invariant color after 6 months.Under 40 ℃ of acceleration environments, almost there is not decomposition, 60 ℃ of conditions have decomposition after following 2 months slightly, and this product is fixed tentatively 2 years effect duration.
Preliminary Clinical Observation explanation by above-mentioned a series of research and nearly 100 examples, low concentration 0.1-0.2% silver nitrate ointment is as 0.5% silver nitrate aqueous solution and 2% silver sulfadiazine, has broad-spectrum, very strong antibacterial ability, it is nontoxic to human body to absorb the back, be applicable to treatment large-area burns and other infectious surgical diseases, contrast with 0.5% silver nitrate aqueous solution, it can discharge silver ion lentamente, do not turn black, long action time, be difficult for causing that power and water separates the matter disorder, and reduce to 0.1～0.2% from 0.5%, further slowed down part and systemic toxic side effect with concentration.This medicine and silver sulfadiazine ointment contrast also have obvious advantage, and for example local irritation is little, can not cause pain, not suppress epidermal growth, be difficult for irritated, be difficult for producing Resistant strain, and the renal function injury of having avoided sulfadiazine to cause, reach the advantage of developing orthonitric acid silver aqueous solution and silver sulfadiazine ointment, overcome the shortcoming that they exist separately, good effect, toxicity is low, and is easy to use, low price can be prevented and treated the purpose of design that burn and other surgical wound infect new drug.
Further specify the present invention below in conjunction with embodiment and Comparative Examples.
Embodiment 1:
Take by weighing gelatin 2 grams, add 40 milliliters in warm water, soak 80 ℃ of expansion post-heating, make it be fused into rubber cement, get glycerol 15 gram and add in the gelatine sizes, stir glycerol gelatin matrix, get sodium carboxymethyl cellulose 3.8 grams, dimethicone 3.0 grams join in the glycerol gelatin matrix, stir, get beta-schardinger dextrin-and add 20 milliliters in water, it is standby to heat 60 ℃ of dissolvings, get silver nitrate 0.1 gram, potassium nitrate 0.005 gram joins in the beta-schardinger dextrin-liquid after adding 5 milliliters of dissolvings of water, joins in the glycerol gelatin matrix to stir again, get lemon yellow 0.005 gram and add excess water dissolving back adding to stir in the above-mentioned substrate, uniform ointment is placed vacuum chamber to take out to degas bubble, get final product fill, Packaging Bottle is cleaned, the cold drying poison that goes out, with ointment sampling chemical examination, quantitative filling seals, label the vanning warehouse-in.
Embodiment 2:
Except silver nitrate was 0.2 gram (content 0.2%), all the other were with embodiment 1.
Embodiment 3:
Except silver nitrate was 0.5 gram (content 0.5%), all the other were with embodiment 1.
Comparative Examples 1:
Ointment base: except not adding silver nitrate, other is with embodiment 1.
Comparative Examples 2:
Adopt commercially available SHAOTANGNING OINTMENT, contain 2% silver sulfadiazine in this ointment.
Below the further effect of contrast ointment of the present invention and 2.0% silver sulfadiazine:
Chemical analysis shows that silver nitrate ointment (0.1～0.5%) water solublity is strong, and its effective ingredient silver ion degree of dissociation is big, is 550～650PPM.Ag in 0.1% silver nitrate ointment
+Be 597PPM, and the Ag in 2% silver sulfadiazine (AgSD)
+Be 270PPM(200～300PPM), the former is about 2.21 times of the latter.
1, external inhibition zone test:
The external inhibition zone result of the test of table 1. (millimeter)
As seen from Table 1,0.1% silver nitrate ointment is antibacterial obviously greater than 2% silver sulfadiazine ointment (P＜0.05).
2, bacteriostatic test in the body:
Get healthy white rabbit, unhairing is scalded with 98% hot water partial-depth, with 0.5 milliliter of staphylococcus aureus (1 * 10
9/ milliliter) evenly coats wound surface, got wound surface middle part eschar and undertissue's inspection bacterial population thereof, and listed in table 2 in the 4th day.
The staphylococcus aureus number relatively under the table 2. scald rabbit eschar
As seen from Table 2, make bacterial population be starkly lower than blank substrate, also be lower than 2% sulphur and be subjected to pyrimidine silver ointment with ointment of the present invention.
3, the influence that human epidermal cell is grown:
Adopt human epidermal cell cultivation and 3H-TdR to mix method, observe influence, the results are shown in table 3 the human epidermal cell growth.
Table 3. epidermis cell counting
As known from Table 3, the AgNO of embodiment
3Ointment does not suppress epithelial cell growth, and 2% silver sulfadiazine very obviously descends cell.
4,2% silver sulfadiazine is distributed in patient burn wound scorching hot sensation of pricking, and uses 0.1～0.2% silver nitrate not only non-stimulated but also can also relax the inherent pain of wound surface to patient.
5,0.1～0.2% silver nitrate keeps in Dark Place in basic invariant color in two years.
6,0.1～0.2% silver nitrate does not cause general toxicity and anaphylaxis, and silver sulfadiazine has general toxicity and anaphylaxis.
In sum, it combines the advantage of 0.5% water-soluble silver nitrate aqueous solution and 2.0% flamazine ointment of the present invention, has overcome their shortcoming. Be a kind of good effect, toxicity is low, and is easy to use, the new drug that low-cost control burn and other surgical wound infect.
Claims (2)
1, a kind of silver nitrate ointment is a principal agent with the silver nitrate, is aided with dimethicone, beta-schardinger dextrin-, sodium carboxymethyl cellulose, gelatin, glycerol, potassium nitrate, lemon yellow, water, and prescription of the present invention (weight %) is:
A. principal agent:
Silver nitrate 0.1～0.2
B. accessory drugs:
Beta-schardinger dextrin-2.0
Sodium carboxymethyl cellulose 3.8
Gelatin 2.0
Dimethicone 3.0
Potassium nitrate 0.005
Glycerol 15.00
Lemon yellow 0.005
C. water surplus
A+B+C=100 weight %
2, a kind of technology of producing the ointment of claim 1 is:
(1) get gelatin and add 40 milliliters in warm water, soak 80 ℃ of expansion post-heating, make it dissolve into rubber cement,
(2) get glycerol and add in the gelatine size, stir glycerol gelatin matrix,
(3) get sodium carboxymethyl cellulose, dimethicone adds in the glycerol gelatin matrix, stir,
(4) get beta-schardinger dextrin-and add 20 milliliters in water, heat 60 ℃ of dissolvings,
(5) get silver nitrate, potassium nitrate adds in the powder-beta-dextrin liquid after adding 5 milliliters of dissolvings of water, add in the glycerol gelatin matrix again to stir,
(6) get the lemon horizontal stroke and stir yellow the adding in the above-mentioned substrate of excess water dissolving back adding,
(7) uniform ointment put taken out the bubble that degass in the vacuum chamber,
(8) Packaging Bottle is cleaned, the cold drying sterilization,
(9) with ointment sampling chemical examination, quantitative filling seals, and labels the vanning warehouse-in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94119842 CN1110557A (en) | 1994-12-14 | 1994-12-14 | Silver nitrate ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94119842 CN1110557A (en) | 1994-12-14 | 1994-12-14 | Silver nitrate ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1110557A true CN1110557A (en) | 1995-10-25 |
Family
ID=5039403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94119842 Pending CN1110557A (en) | 1994-12-14 | 1994-12-14 | Silver nitrate ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1110557A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824363A (en) * | 2012-09-21 | 2012-12-19 | 张晋瑞 | Antibacterial agent |
| CN115300528A (en) * | 2022-07-19 | 2022-11-08 | 右江民族医学院 | Mirabilitum ointment for inhibiting staphylococcus aureus and preparation method and application thereof |
-
1994
- 1994-12-14 CN CN 94119842 patent/CN1110557A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824363A (en) * | 2012-09-21 | 2012-12-19 | 张晋瑞 | Antibacterial agent |
| CN115300528A (en) * | 2022-07-19 | 2022-11-08 | 右江民族医学院 | Mirabilitum ointment for inhibiting staphylococcus aureus and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278896B (en) | Chitosan nano silver gel agent and uses thereof | |
| KR20010022825A (en) | Use of locally delivered metal ions for treatment of periodontal disease | |
| US7392762B2 (en) | Method for site-specific application of topical medicants to aquatic animals | |
| US4604391A (en) | Treatment of osteitis and osteomyelitis employing thiadiazine compounds | |
| CN1751577A (en) | Composite sterilizing agent contg. silver and zinc, prepn. method and application thereof | |
| US5618847A (en) | Medicinal feed for the systemic treatment of ectoparasitic and ectobacterial diseases of fish | |
| CN1090506C (en) | Application of lysozyme dimer | |
| CN106692171B (en) | Compound selamectin external drop for pets as well as method and application thereof | |
| EP1310246B1 (en) | Use of bronopol for the treatment of diseases in fish eggs | |
| Barillo | Topical antimicrobials in burn wound care: a recent history | |
| CN105012581A (en) | Fresh aloe antibacterial composite, application and preparing method of fresh aloe antibacterial composite | |
| CN1110557A (en) | Silver nitrate ointment | |
| DK2170081T3 (en) | Antimicrobial preparations | |
| CN107595882A (en) | A kind of preparation method of the anti-biotic material containing nanometer gold silver | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| US4474759A (en) | Method of treating bacterial, viral or parasitic diseases | |
| RU2052266C1 (en) | Method of cow hepatosis treatment | |
| CN101062066A (en) | Compound isatis-root injection for animals and the preparing method thereof | |
| JP2014513721A (en) | “RENESSANS”, a pharmaceutical composition having antibacterial, antiulcer and immunomodulating effects | |
| RU2145499C1 (en) | Preparation gastropulmin for treatment and prophylaxis of gastro-enteric and respiratory sicknesses in newborn calves and lambs | |
| RU2218167C2 (en) | Method for preparing composite agent "ointment "svf" | |
| RU2320325C1 (en) | Method for treating inspecific mastitis in cows | |
| Knotek | Therapeutics and medication | |
| CN1082372C (en) | Liquid medicine for treatment of bromidrosis, and its preparing method | |
| US20250018083A1 (en) | Novel wound dressing based on cellulose acetate films containing binary metal oxide nanohybrids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |